Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone

By Dr. Matthew Watson

Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera.

More:
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone

Related Post

• Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union - September 23rd, 2024
• Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed - September 23rd, 2024
• Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade - September 23rd, 2024
• Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with... - September 23rd, 2024
• T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union - September 23rd, 2024
• Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - September 23rd, 2024
• Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - September 23rd, 2024
• Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs - September 23rd, 2024
• Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders - September 23rd, 2024
• Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 23rd, 2024
• Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024 - September 23rd, 2024
• Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly... - September 23rd, 2024
• New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release... - September 23rd, 2024
• Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous... - September 23rd, 2024
• Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - September 23rd, 2024
• WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s... - September 23rd, 2024
• Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia - September 23rd, 2024
• GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA... - September 23rd, 2024
• Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement - September 23rd, 2024
• Synergia Medical Successfully Implants First Patients With NAO.VNS™ - September 23rd, 2024
• Tr1X to Participate at Upcoming Healthcare Investment Conferences - September 14th, 2024
• Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 - September 14th, 2024
• Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - September 14th, 2024
• CorMedix Inc. to Present at the Cantor Global Healthcare Conference - September 14th, 2024
• RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress - September 14th, 2024
• Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - September 14th, 2024
• C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial... - September 14th, 2024
• Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - September 14th, 2024
• Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th - September 14th, 2024
• Virbac 2024 half-year results - September 14th, 2024
• Virbac: Information on the departure of Sébastien Huron - September 14th, 2024
• Virbac : the board of directors announces a capital reduction through cancellation of treasury shares - September 14th, 2024
• Virbac : Public release of the Half-Year Financial Report at 30 June 2024. - September 14th, 2024
• Virbac : Half-yearly financial report 2024 - September 14th, 2024
• Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - September 14th, 2024
• Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq - September 14th, 2024
• Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - September 14th, 2024
• Company Statement on FDA Advisory Committee Meeting   - September 14th, 2024
• iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of... - September 14th, 2024
• IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer - September 14th, 2024
• Total number of shares and voting rights in Zealand Pharma on August 30, 2024 - September 3rd, 2024
• IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with... - September 3rd, 2024
• Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update - September 3rd, 2024
• Receipt of Nasdaq Delisting Determination - Plans to Appeal - September 3rd, 2024
• Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop... - September 3rd, 2024
• Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates - September 3rd, 2024
• George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC... - September 3rd, 2024
• Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - September 3rd, 2024
• Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 - September 3rd, 2024
• Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in... - September 3rd, 2024
• PCI Biotech: Employee share option scheme - September 3rd, 2024
• Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK - September 3rd, 2024
• Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today - September 3rd, 2024
• Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 3rd, 2024
• Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and... - September 3rd, 2024
• Amended terms of Idorsia’s 2024 convertible bonds become effective - September 3rd, 2024
• Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine... - September 3rd, 2024
• CARBIOS appoints Tommy Maussin as Chief Marketing Officer and Executive Committee member to develop CARBIOS’ presence with brands worldwide - September 3rd, 2024
• Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate - September 3rd, 2024
• QIAGEN N.V. launches non-US offering of net share settled convertible bonds - September 3rd, 2024
• Structure Therapeutics Announces Participation in Upcoming Investor Conferences - August 27th, 2024
• Notable Labs Announces CEO Transition - August 27th, 2024
• Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference - August 27th, 2024
• Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer - August 27th, 2024
• IO Biotech Announces Participation in Upcoming Investor Conferences - August 27th, 2024
• Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) - August 27th, 2024
• Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors - August 27th, 2024
• BioSyent Declares Third Quarter 2024 Dividend - August 27th, 2024
• Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors - August 27th, 2024
• BioSyent Releases Financial Results for Q2 and H1 2024 - August 27th, 2024
• Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - August 27th, 2024
• Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L. - August 27th, 2024
• Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update - August 27th, 2024
• Telix Announces Reorganisation to Deliver on Strategic Priorities - August 27th, 2024
• ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics - August 27th, 2024
• Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration - August 27th, 2024
• Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH - August 27th, 2024
• European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers... - August 27th, 2024
• Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy - August 27th, 2024
• Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore - August 27th, 2024

Global News Feed Comments Off on Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone | June 27th, 2024

About... Dr. Matthew Watson

Categories

• Bone Marrow Stem Cells (2,928)
• Cardiac Stem Cells (1,262)
• Global News Feed (3,215)
• Integrative Medicine (105)
• IPS Cell Therapy (456)
• Nano medicine (2)
• Regenerative Medicine (44)
• Skin Stem Cells (2,193)
• Spinal Cord Stem Cells (947)
• Stem Cell Therapy (528)

Archives

Recommended Sites

• California Stem Cell Research
• Cord Blood Banking
• Gene Therapy Breakthroughs
• Immortality Medicine
• Medical School Review
• Nano Technology American Physicians
• Videos Of Stem Cell Therapy